Jiangsu Jibeier Pharmaceutical Co Ltd (688566) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Jiangsu Jibeier Pharmaceutical Co Ltd (688566) has a cash flow conversion efficiency ratio of 0.005x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥11.07 Million ≈ $1.62 Million USD) by net assets (CN¥2.37 Billion ≈ $346.78 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 688566 equity financing ratio to measure how much of total assets are equity-financed.
Jiangsu Jibeier Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Jiangsu Jibeier Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 688566 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Jiangsu Jibeier Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Jiangsu Jibeier Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Media and Games Invest PLC
XETRA:M8G
|
0.001x |
|
Gokul Agro Resources Limited
NSE:GOKULAGRO
|
0.069x |
|
Delta Israel Brands Ltd
TA:DLTI
|
0.164x |
|
Foosung
KO:093370
|
-0.023x |
|
Ton Yi Industrial Corp
TW:9907
|
0.042x |
|
Sun Create Electronics Co., Ltd
SHG:600990
|
0.058x |
|
AECI Ltd
JSE:AFE
|
0.035x |
|
Ruitai Materials Technology Co Ltd
SHE:002066
|
-0.153x |
Annual Cash Flow Conversion Efficiency for Jiangsu Jibeier Pharmaceutical Co Ltd (2016–2025)
The table below shows the annual cash flow conversion efficiency of Jiangsu Jibeier Pharmaceutical Co Ltd from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see 688566 market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥2.45 Billion ≈ $358.46 Million |
CN¥248.30 Million ≈ $36.33 Million |
0.101x | +6.11% |
| 2024-12-31 | CN¥2.25 Billion ≈ $329.81 Million |
CN¥215.29 Million ≈ $31.50 Million |
0.096x | +14.41% |
| 2023-12-31 | CN¥1.91 Billion ≈ $279.55 Million |
CN¥159.50 Million ≈ $23.34 Million |
0.083x | -6.15% |
| 2022-12-31 | CN¥1.69 Billion ≈ $247.93 Million |
CN¥150.72 Million ≈ $22.06 Million |
0.089x | -4.97% |
| 2021-12-31 | CN¥1.61 Billion ≈ $235.34 Million |
CN¥150.56 Million ≈ $22.03 Million |
0.094x | +25.73% |
| 2020-12-31 | CN¥1.58 Billion ≈ $230.67 Million |
CN¥117.36 Million ≈ $17.17 Million |
0.074x | -69.66% |
| 2019-12-31 | CN¥470.46 Million ≈ $68.84 Million |
CN¥115.45 Million ≈ $16.89 Million |
0.245x | -10.41% |
| 2018-12-31 | CN¥357.68 Million ≈ $52.34 Million |
CN¥97.97 Million ≈ $14.34 Million |
0.274x | +8.12% |
| 2017-12-31 | CN¥440.76 Million ≈ $64.50 Million |
CN¥111.66 Million ≈ $16.34 Million |
0.253x | +134.16% |
| 2016-12-31 | CN¥363.15 Million ≈ $53.14 Million |
CN¥39.29 Million ≈ $5.75 Million |
0.108x | -- |
About Jiangsu Jibeier Pharmaceutical Co Ltd
Jiangsu Jibeier Pharmaceutical Co., Ltd., a pharmaceutical company, engages in the drug research and development and production in China. The company's products cover multiple therapeutic areas such as increasing white blood cells, fighting hypertension, enhancing immunity, treating joint diseases, fighting eye infections, treating bronchitis, protecting liver function, etc. It is also developing… Read more